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In anaesthetized paralysed, mechanically ventilated pigs,
the vascular and respiratory effects of 80 ppm nitric
oxide (NO) inhaled for 6 rain were evaluated. To evoke
different levels of smooth muscle contraction ET-1 or
PAF, mediators involved in pulmonary disorders, were
used. In control conditions, inhaled NO caused selective
pulmonary vasodilatation without affecting respiratory
resistances. This pulmonary vascular activity influenced
the distensibility ofthe respiratory system and decreased
inspiratory work. ET-1 administration significantly in-
creased pulmonary arterial pressure and modestly
changed mechanical properties of the respiratory
system, while PAF caused potent vasoconstriction and
bronchoconstriction associated with a marked change in
volume-pressure relationship. In both cases, the changes
in vascular and mechanical properties of the respiratory
system increased inspiratory work. The vascular and res-
piratory activities of inhaled NO were correlated with
preconstriction levels. The data show that the com-
bination of vascular and respiratory effects improves
pulmonary function, suggesting that inhalation of NO
is a possible therapeutic approach for obstructive and
inflammatory pulmonary diseases.
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Introduction
The discovery of endothelium-derived relaxing
factor and its subsequent identification as nitric oxide
(NO) revealed a new regulatory mechanism for
bronchomotor and vascular tone.1- NO has been
detected in exhaled air, with stable concentrations at
rest and increased concentrations after challenges in
sensitized animals with antigen or in asthmatic
patients. This implies that NO is endogenous and it
may be one of the recently described epithelium-
derived relaxing factors. 1,11
Recently, it has been demonstrated that NO
synthase can be induced by endogenous platelet
activating factor (PAF). 12 This is a phospholipid me-
diator that causes bronchoconstriction, lung inflam-
mation and hyperresponsiveness. PAF is released by
inflammatory cells in obstructive, inflammatory and
asthmatic disorders. 13 Therefore, it has been sug-
gested that PAF might be a mediator of endothelin-
induced bronchoconstriction in the guinea-pig.
14
Endothelin-1 (ET-1) is a potent vasoconstrictor15 and
bronchoconstrictor peptide16-18 produced by
endothelial cells and degraded predominantly in the
pulmonary vasculature. ET-1, like PAF, also has a
pathophysiological role. Immunoreactive ET-1 has
been recovered in bronchoalveolar lavage fluid of
asthmatic patients and high plasmatic levels of this
peptide have been found in adult respiratory distress
syndrome (ARDS). 19
ET-1 activates the cyclooxygenase pathway
2 and
induces release of endothelial-derived relaxing fac-
tor. Recently it has been-suggested that inhalation of
NO might be used as a therapeutic strategy to reduce
symptoms of obstructive and hypertensive pul-
monary disorders.21,22 These last, changing the
mechanical properties of the respiratory system, can
increase the respiratory work, with a limiting effect
on pulmonary activity.
The purpose of this study was to evaluate the
effects of inhaled NO on mechanical properties of
respiratory system during bronchoconstriction and
pulmonary hypertension caused by administration of
ET-1 or PAF, mediators involved in pulmonary disor-
ders. We have also used ET-1 and PAF to see whether
or not NO activity is correlated with the degree of
bronchoconstriction.
Materials and Methods
Twelve Large White pigs, of either sex, weighing
20.4 + 1.7 (SEM) kg, were used. The animals, sedated
with 1% propi0nylpromazine hydrochloride
(0.05 ml/kg, i.m.) were anaesthetized with 15 mg/kg
thiopental-sodium injected into the auricular vein.
The depth of anaesthesia was maintained by infu-
sion, drop by drop, of thiopental-sodium (9 mg/kg/
h). The animals, tied in the supine position on a
heated operating table, were tracheostomized, para-
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lysed with pancuronium bromide (0.02 mg/kg, i.v.)
and mechanically ventilated (Servoventilator Sie-
mens 900 C). When necessary, additional paralysing
drug was administered during the experiments.
An endotracheal tube was inserted into the lower
portion of the extrathoracic trachea. A heated
pneumotachograph (Fleisch No 2, Fleisch Lausanne,
Switzerland) was connected to the proximal end of
the endotracheal tube and the ’Y’ piece of the vent-
ilator to evaluate respiratory flow. Electronic integra-
tion of the flow signal gave the tidal volume. The
pressure drop across the two ports of the
pneumotachograph was measured with a differential
pressure transducer (Statham PM15, 10846). The re-
sponse of the pneumotachograph was linear over the
experimental range of flows. To reduce the effects of
the compliance of the system on the mechanical
measurements, a fixed length standard low-compli-
ance tube was used (2 cm ID, 60 cm long) to connect
the animals to the ventilator. The equipment flow
resistance was 0.5 cm HaO/1/s and the equipment
dead space was 29.5 ml.
A balloon-tipped catheter (Swan Ganz 5F) was
introduced into the left brachial vein and allowed to
float through the right heart to the pulmonary artery.
Polyethylene catheters were inserted into the right
femoral artery to record blood pressure and into the
right femoral vein for drug administration. Systemic
and pulmonary arterial pressure were recorded by
connecting the catheters to a fluid-filled capacitance
manometer (Bell & Howell 4-422). All parameters
were calibrated independently and simultaneously
recorded on a multichannel pen recorder (model
8K40; NEC San-Ei Instruments, Ltd, Tokyo, Japan).
Heart rate, mean arterial pressure and mean pul-
monary pressure (MPAP) were evaluated from the
polygraph tracings.
Procedure and data analysis: The baseline ventilator
settings were a fixed inflation volume of 0.2 + 0.01
(SEM) and a fixed inspiratory flow of 0.25 + 0.01
(SEM) 1/s. Respiratory frequency was 23 + 2 (SEM)
breaths/min and the ratio of inspiratory time to total
breathing cycle duration was 0.33 + 0.01 (SEM). Res-
piratory mechanics values were assessed by the con-
stant flow inspiratory occlusion method. ’3 For each
breath, airway occlusion was followed by a rapid
initial drop in tracheal pressure and was maintained
until an apparent plateau, representing the end-in-
spiratory elastic recoil pressure, was achieved (5-6 s).
The difference between the peak of tracheal pressure
and plateau pressure, divided by the immediately
preceding steady flow, provided the total resistance
of the airways (Rrs). The inspiratory work (W) of
respiratory system was evaluated as area of the
volume-pressure changes (AV/AP).
Protocol:
1. After evaluation of control values, obtained when
the animals were breathing air through the
servoventilator, nitric oxide (NO) was adminis-
tered through the servoventilator for 6 min. The
inspired gas was a precise mixture of oxygen and
nitrogen immediately diluted with NO to produce
the desired concentration of inspired NO
(80 ppm). With volumetrically calibrated
flowmeters, NO in the bag (mixture of 235 ppm
NO in pure N2) was substituted for pure N to give
the desired concentration of inspired NO at a
concentration of inspired oxygen (FIO2) of
0.6-0.7. We used 60-70% oxygen to avoid
hypoxic vasoconstriction.
2. After recovery to baseline values, six of the 12 pigs
were treated with ET-1, administered through the
Swan-Ganz catheter at a dose of 200 pmol/kg, as
previously reported.24 NO was inhaled at the peak
of ET-1 dependent vascular and respiratory effects
(about 10 min).
3. After recovery to baseline values, the other six pigs
were treated with PAF, freshly mixed in normal
saline solution, administered i.v. at a dose of
50 ng/kg. This dose, as previously reported,25 was
sufficient to ensure significant and reproducible
haemodynamic and respiratory effects in pigs. The
activity of inhaled NO was evaluated at the peak
of PAF-dependent vascular effects (5 min).
Data analysis and statistics: Results are expressed as
means + SEM. The significance of differences be-
tween two sets of data was assessed by the two-tailed
t-test for paired data. A significant difference was
defined as P < 0.05.
Results
In all experimental conditions inhaled NO did not
modify systemic blood pressure or heart rate, but
changed pulmonary vascular pressure and mechani-
cal properties of respiratory system.
Figure 1A shows that in control conditions NO
inhalation caused a significant decrease in pulmo-
nary vascular pressure. This decrease in MPAP was
associated with a change in the AV/AP relationship
of the respiratory system, as evidenced in Fig. lB.
In control conditions this volume-pressure relation-
ship, although linear between 0.05 and 0.2 1, exhib-
ited a ’knee’ at the lower volumes. Inhaled NO
modified the slope (from 19.07 to 20.17 1/cm H20)
but did not affect the ’knee’ or the linearity of the
curve. The change in slope after NO inhalation
reflects improvement of the pulmonary function, that
is, significantly decreases respiratory system work
(Fig. lC), while respiratory resistance did not change
(Fig. 1D).



















0 5 10 15
AP (cmHO)
C NO
FIG. 1. Effects of inhaled NO in control conditions (C). (A) Mean pulmonary arterial pressure (MPAP);
(B) average volume-pressure (AV/AP) relationships of respiratory system obtained in control condi-
tions (m) and after NO inhalation (----) evaluated at fixed volumes; above 0.05 lines were
computed by linear regression analysis. (C) Inspiratory work of respiratory system (W); (D)
respiratory resistance (Rrs). Values are expressed as means SEM. *p < 0.05 NO vs. control
conditions.
Effects ofNO inhalation after ET-1 administration:
NO inhaled after ET-1 administration completely
counteracted pulmonary hypertension and the
changes in mechanical properties of respiratory sys-
tem evoked by ET-1.
The changes in mean pulmonary arterial pressure
due to ET-1 administration and NO inhalation are
reported in Fig. 2A. The data show that the admin-
istration of ET-1 significantly increased MPAP
(141.32 _+ 2.96%), which was completely counter-
acted by NO inhalation, which brought the MPAPto
values lower than controls (78.6 _+ 6.37%).
Figure 2B shows the AV/AP relationship obtained
in control conditions, after treatment with ET-1 and
after NO inhalation. The modest displacement of this
relationship caused by ET-1 administration was com-
pletely reversed by inhalation of nitric oxide.
The changes in respiratory system work are re-
ported in Fig. 2C. The increased respiratory work
(107.13 +_ 2.41%) caused by ET-1 administration was
completely restored to control values (98.76 _
2.93%)
by NO inhalation. Changes in respiratory work were
associated with changes in the respiratory resistances
(Fig. 2D). In fact, ET-1 administration modestly in-
creased Rrs. Even though this change was not signifi-
cant., inhaled NO reduced Rrs toward control values.
Effects ofNO inhalation after PAF administration:
PAF caused marked pulmonary vasoconstriction and
changes in the mechanical properties of respiratory
system. NO inhaled after PAF exerted a strong relax-
ing effect, and, though only partially, counteracted
the pulmonary vascular and respiratory effects due to
PAF administration. The significant PAF-dependent
increase in pulmonary arterial pressure
(274.3 + 15.22%) was almost completely restored to
control values (122.6 + 5.96%) by NO inhalation
(Fig. 3A).
The slope and the linearity of the AV/AP curve
observed in control conditions were greatly affected
by PAF administration, as evidenced in Fig. 3B. In
this case too, inhalation of nitric oxide reduced the
PAF-dependent changes, without restoring the lin-
earity of the curve.
The changes in respiratory system work caused by
PAF administration and NO inhalation are reported
in Fig. 3C. Data show that the PAF-dependent
significant increase in work (171.6 + 10.7%) was sig-
nificantly reduced by NO inhalation (118.1 + 4.56%),
without restoring the respiratory work to the control
values. The resistance of the respiratory system after
PAF administration and NO inhalation is reported in
Fig. 3D. The increase in Rrs of 320.88 + 26.05%
due to PAF was partially counterbalanced by NO
inhalation, which restored Rrs near to the control
values (145.97 + 11.14%).
Discussion
This study demonstrates that in anaesthetized,
paralysed pigs inhaled NO acts as a selective pulmon-.
ary vasodilator and improves the mechanical prop-
erties of the respiratory system. These effects are
present in control conditions and also after
pretreatment with ET-1 or PAF, two agents involved
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FIG. 2. Effects of NO inhaled after ET-1 administration. (A) Mean pulmonary arterial pressure (MPAP);
(B) volume-pressure (zV/zP) relationships of respiratory system obtained in control conditions (--),
after ET-1 administration and after NO inhalation ). (C) Inspiratory work of respiratory
system (W); (D) respiratory resistance (Rrs). Values are expressed as means SEM. *p < 0.05 ET-


















0 10 20 30 C PAF NO
P (cmH=O)
FIG. 3. Effects of NO inhaled after PAF administration. (A) Mean pulmonary arterial pressure (MPAP);
(B) volume-pressure (zV/zP) relationships of respiratory system obtained in control conditions (--),
after PAF administration and after NO inhalation ). (C) Inspiratory work of respiratory
system (W); (D) respiratory resistance (Rrs). Values are expressed as means +/- SEM. *p < 0.05 PAF
or NO vs. control conditions. Op < 0.05 NO vs. PAF administration.
in many respiratory diseases characterized by
bronchoconstriction and pulmonary hypertension.
ET-1, known as a potent vasoconstrictor and
bronchoconstrictor agent,15-’ in the pig causes only
modest contraction of airways smooth muscles but
pulmonary hypertension similar to that observed in
other species. ’4,’6,’7 As suggested by Battistini et al.,TM
the bronchopulmonary action of ET-1 may be medi-
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ated by endogenous release of PAF which, like
endothelin, has a pathophysiological role in lung
dysfunctions. In the pig, 50 ng/kg PAF is a strong
constrictor of pulmonary vascular and bronchial
smooth muscles.’5
An important new regulatory mechanism of the
pulmonary and systemic circulation>8 is attributed to
nitric oxide, also known as endothelium-derivedNO reverses ET-1 and PAF effects
relaxing factor. Recent observations demonstrate that
when NO is inhaled, it acts as a selective local
pulmonary vasodilator, without causing systemic
vasodilatation.6,7,28
Our results confirm these findings and also suggest
that in the pig NO has selective pulmonary
vasodilator activity not only on preconstricted vascu-
lar smooth muscle, but also on normal vascular tone.
Using ET-1 and PAF, which cause two different
degrees of contraction, we also demonstrated that
the NO vasodilator activity is correlated with the
degree of vasoconstriction, because its effect is
greater after administration of PAF, which causes a
stronger pulmonary hypertension. The NO-depend-
ent pulmonary vasodilator activity improves respira-
tory function. In fact, in control conditions the
vasodilator activity of inhaled NO improves the dis-
tensibility of the respiratory system, as evidenced by
displacement of the kV/AP relationship, even if it did
not affect respiratory resistance. The ’knee’ observed
in the AV/AP curve at lower volumes in anaesthe-
tized, paralysed, mechanically ventilated pigs, simi-
larly to that observed in cats,29 reflects different
stresses within the tissue elements. The persistence
of this ’knee’ when NO is inhaled in control condi-
tions shows that stress inequalities are not affected
by NO, which essentially acts on vascular smooth
muscle.
The area enclosed between the AP vs. AV curve
represents the inspiratory work of the respiratory
system.3 The displacement of the AV/AP curve to the
left by NO is an index of decreased work done by the
respiratory system. Therefore, the present results
show that when 80 ppm NO is inhaled for 6 min, it
improves pulmonary vascular and mechanical func-
tions of the respiratory system. The vasodilatation
associated with the improvement of lung distensibil-
ity and with the decrease in inspiratory work favours
the redistribution of blood flow to better ventilated
areas of the lungs, improving gas exchange.31,3 A
marked improvement of oxygen exchange and arte-
rial oxygen tension caused by inhalation of
5-80 ppm of NO was also seen recently by Falke et
al. in patients with ARDS and by Roberts et al.4 in
neonates with persistent pulmonary hypertension of
the newborn. Recent observations have shown that
inhaled NO causes bronchodilatation and not simply
vasodilatation of ventilated lung regions.
21 In fact,
inhaled NO molecules are extremely lipophilic5 and
can diffuse through the bronchial epithelial barrier to
reach airway smooth muscle and to produce airway
relaxation.
In the pig, bronchodilatation appears only when
airways smooth muscles are precontracted, because
changes in Rrs were observed only when NO was
inhaled after ET-1 or PAF administration. The bron-
chial preconstriction level influences the degree of
response to inhaled NO similarly to that of the
pulmonary vascular bed. When NO was inhaled after
ET-1, causing modest contraction, the bronchomotor
and the vascular tones were completely restored.
When NO was inhaled after PAF administration,
exerting more potent vasoconstriction and bron-
choconstriction, the vasodilator and bronchodilator
effects were greater, even though NO only partially
reversed PAF-dependent action.
The complex vasoactive and respiratory effects of
PAF are characterized not only by pulmonary hyper-
tension and potent bronchoconstriction, but also by
lung oedema3<7 and decreased lung distensibility. 38
Oedema and parenchymal damage due to PAF ad-
ministration may alter the linearity of the AV/AP
relationship, also in the range between 0.05-0.2 1.
The displacement to the right and the non-linearity
of the AV/AP curve observed after PAF evidence the
reduction in pulmonary compliance and the non-
homogeneous lung distensibility. Inhaled NO, by its
vasodilator activity, reduces pulmonary PAF-depend-
ent hypertension and decreases the accumulation of
extravascular lung water. This effect, associated with
marked bronchodilator activity, is responsible for the
great displacement of the AV/AP curve to the left.
Although inhaled NO does not completely restore
the slope and the linearity of the curve and
only partially reduces the PAF-dependent
bronchoconstriction, the changes observed in the
mechanical properties of the respiratory system sug-
gest that inhaled NO might be a potent therapeutic
approach for hypertensive and obstructive lung dis-
eases.
It is known that obstructive pulmonary diseases
impose significant amounts of respiratory work.
During a breathing cycle, work must be done to
overcome flow-resistive forces, the magnitude of
which depends on the flow-resistance and respira-
tory frequency.9 To avoid the frequency-depend-
ence of work, we ventilated the pigs at constant flow
and volume, and to induce two different degrees
of bronchoconstriction, causing different flow
resistances, we used ET-1 and PAF. A greater flow-
resistance requires a greater pressure-gradient and
hence more work to overcome flow-resistive forces.
PAF causing an increase in respiratory resistance
more marked than ET-1 does, induces a greater
increase in inspiratory work. Therefore, NO’s
vasodilator activity, associated with a marked de-
crease in respiratory resistance and improved lung
distensibility, favours pulmonary function, reducing
inspiratory work. In this case, too, NO activity is
correlated with the degree of mechanical impairment
of the respiratory system, as evidenced by the greater
decrease in inspiratory work observed when NO is
inhaled after PAF.
In conclusion, the present data gives evidence that
nitric oxide causes not only selective pulmonary
vasodilatation but also bronchodilatation. Pulmonary
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vasodilatation favours arterial oxygenation and
reduction of pulmonary oedema, while
bronchodilatation, due to a direct action of nitric
oxide on airways smooth muscle, reduces respiratory
resistance. The only partial reduction of vascular and
respiratory PAF-dependent changes suggests that the
response to inhaled NO is dose- and time-depend-
ent. The association of vascular and bronchial effects
improves lung distensibility, reducing respiratory
work. These advantages, associated with rapidity of
effects and ease of administration, in the absence of
systemic hypotensive effects, make inhaled NO a
therapeutically important approach, not only in ob-
structive respiratory distress syndrome but also in
inflammatory allergic endothelin-1 and/or platelet
activating factor-mediated diseases.
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